Efficacy and Safety of ATP Citrate Lyase Inhibitors

Efficacy and Safety of ATP Citrate Lyase Inhibitors - Efficacy and Safety of ATP Citrate Lyase Inhibitors

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000059854

Enrollment

Registered

2025-11-22

Start date

2025-11-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

refractory dyslipidemia

Interventions

Patients with treatment-resistant dyslipidemia will be administered 180 mg of an ATP citrate lyase inhibitor daily and observed for 12 months.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: refractory dyslipidemia

Exclusion criteria

Exclusion criteria: Doctor's decision not to register to this regimen

Design outcomes

Primary

Measure	Time frame
LDL	—

Secondary

Measure	Time frame
1) HDL, T-cho, TG 2)BUN, Cr, eGFR, cystatin C, U-alb, 3) AST, ALT 4) CPK 5)hs-CRP 6) HbA1c, CPR, insulin 7) LP (a), ox-LDL, RLP-cho, DHA, AA, EPA, DPA 8) Apo protein, Lipo prtotein	—

Countries

Japan

Contacts

Public ContactAkira Sezai

Nihon University School of Medicine Department of Cardiovascular Surgery

asezai.med@gmail.com03-3972-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026